MX2010006995A - 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use. - Google Patents

5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.

Info

Publication number
MX2010006995A
MX2010006995A MX2010006995A MX2010006995A MX2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A
Authority
MX
Mexico
Prior art keywords
phenyl
substituted
oxadiazolones
medical use
oxadiazolone
Prior art date
Application number
MX2010006995A
Other languages
Spanish (es)
Inventor
David Alexander Learmonth
Laszlo Erno Kiss
Humberto Dos Santos Ferreira
Patricio Manuel Vieira Araujo Soares Da Silva
Alexander Beliaev
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX2010006995A publication Critical patent/MX2010006995A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)

Abstract

The present invention relates to compounds having a 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase). (I).
MX2010006995A 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use. MX2010006995A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US930207P 2007-12-27 2007-12-27
PCT/PT2008/000054 WO2009084970A1 (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use

Publications (1)

Publication Number Publication Date
MX2010006995A true MX2010006995A (en) 2010-08-18

Family

ID=40361548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006995A MX2010006995A (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.

Country Status (14)

Country Link
EP (1) EP2238131A1 (en)
JP (1) JP2011507952A (en)
KR (1) KR20100111691A (en)
CN (1) CN101959881A (en)
AR (1) AR069970A1 (en)
AU (1) AU2008344032A1 (en)
BR (1) BRPI0821482A2 (en)
CA (1) CA2710743A1 (en)
CL (1) CL2008003895A1 (en)
IL (1) IL206419A0 (en)
MX (1) MX2010006995A (en)
TW (1) TW200932732A (en)
WO (1) WO2009084970A1 (en)
ZA (1) ZA201005306B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074978A1 (en) * 2008-12-23 2011-03-02 Bial Portela & Ca Sa 3-N-ARIL-1,3,4-OXADIAZOLONAS 5-O-SUBSTITUTED FOR USE IN PAIN TREATMENT AND PROCEDURE OF OBTAINING
AR076687A1 (en) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc ISOXAZOLINS AS INHIBITORS OF THE AMIDAHIDROLASA OF FATTY ACIDS AND PHARMACEUTICAL COM-POSITIONS CONTAINING THEM
WO2010151160A1 (en) * 2009-06-24 2010-12-29 Bial - Portela & Ca., S.A. O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931843A1 (en) * 1989-09-23 1991-04-04 Bayer Ag SUBSTITUTED 1,3,4-OXA (THIA) DIAZOLINONE PROCESS FOR THEIR PREPARATION AND THEIR USE OF THE CONTROL OF ENDOPARASITES
DE19942354A1 (en) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, their manufacture and use in medicinal products
EP1448538A1 (en) * 2001-11-15 2004-08-25 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10208987A1 (en) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxy-1,3,4-oxidiazol-2-ones, their preparation and use in drugs
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase

Also Published As

Publication number Publication date
CN101959881A (en) 2011-01-26
AU2008344032A1 (en) 2009-07-09
ZA201005306B (en) 2011-04-28
AR069970A1 (en) 2010-03-03
CA2710743A1 (en) 2009-07-09
KR20100111691A (en) 2010-10-15
JP2011507952A (en) 2011-03-10
CL2008003895A1 (en) 2010-06-25
AU2008344032A8 (en) 2010-08-19
EP2238131A1 (en) 2010-10-13
TW200932732A (en) 2009-08-01
WO2009084970A1 (en) 2009-07-09
IL206419A0 (en) 2010-12-30
BRPI0821482A2 (en) 2015-07-14

Similar Documents

Publication Publication Date Title
TN2011000291A1 (en) Purine compounds
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
TN2009000509A1 (en) Pyrazole carboxylic acid amides useful as microbiocides
MX2009008099A (en) Compounds for the prevention and treatment of cardiovascular diseases.
MX2010007952A (en) Insecticidal arylpyrrolines.
MY151295A (en) Pyrimidyl indoline compound
UA102817C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR AGOMELATINE SYNTHESIS
MX2012003982A (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions.
IL193252A0 (en) N-hydroxyacrylamide compounds
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
MX2012004780A (en) Akt inhibitors.
UA102220C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR THE SYNTHESIS OF AGOMELATINE
MX2011011776A (en) Triptolide prodrugs.
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
MX2010010877A (en) Compounds and compositions as itpkb inhibitors.
MX2010006995A (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use.
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors
MX2012007426A (en) Amino-heteroaryl derivatives as hcn blockers.
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2009097973A3 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2010103273A3 (en) Essential fatty acid compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal